Annual Revenue
$424.00 K
-$53.00 K-11.11%
December 31, 2023
Summary
- As of February 8, 2025, VYNE annual revenue is $424.00 thousand, with the most recent change of -$53.00 thousand (-11.11%) on December 31, 2023.
- During the last 3 years, VYNE annual revenue has fallen by -$20.57 million (-97.98%).
- VYNE annual revenue is now -97.98% below its all-time high of $20.99 million, reached on December 31, 2020.
Performance
VYNE Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Revenue
$121.00 K
-$77.00 K-38.89%
September 30, 2024
Summary
- As of February 8, 2025, VYNE quarterly revenue is $121.00 thousand, with the most recent change of -$77.00 thousand (-38.89%) on September 30, 2024.
- Over the past year, VYNE quarterly revenue has dropped by -$77.00 thousand (-38.89%).
- VYNE quarterly revenue is now -98.96% below its all-time high of $11.69 million, reached on June 30, 2020.
Performance
VYNE Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM Revenue
$493.00 K
+$7000.00+1.44%
September 30, 2024
Summary
- As of February 8, 2025, VYNE TTM revenue is $493.00 thousand, with the most recent change of +$7000.00 (+1.44%) on September 30, 2024.
- Over the past year, VYNE TTM revenue has increased by +$7000.00 (+1.44%).
- VYNE TTM revenue is now -97.65% below its all-time high of $20.99 million, reached on December 31, 2020.
Performance
VYNE TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
VYNE Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -11.1% | -38.9% | +1.4% |
| 3 y3 years | -98.0% | +1916.7% | +3.4% |
| 5 y5 years | -96.0% | +1916.7% | +3.4% |
VYNE Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -54.5% | at low | -55.7% | +1916.7% | -47.0% | +39.3% |
| 5 y | 5-year | -98.0% | at low | -99.0% | +1916.7% | -97.7% | +39.3% |
| alltime | all time | -98.0% | at low | -99.0% | +1916.7% | -97.7% | +39.3% |
VYNE Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $121.00 K(-38.9%) | $493.00 K(+1.4%) |
| Jun 2024 | - | $198.00 K(+102.0%) | $486.00 K(+14.9%) |
| Mar 2024 | - | $98.00 K(+28.9%) | $423.00 K(-0.2%) |
| Dec 2023 | $424.00 K(-11.1%) | $76.00 K(-33.3%) | $424.00 K(+19.8%) |
| Sep 2023 | - | $114.00 K(-15.6%) | $354.00 K(-13.0%) |
| Jun 2023 | - | $135.00 K(+36.4%) | $407.00 K(+2.3%) |
| Mar 2023 | - | $99.00 K(+1550.0%) | $398.00 K(-16.6%) |
| Dec 2022 | $477.00 K(-48.8%) | $6000.00(-96.4%) | $477.00 K(-35.9%) |
| Sep 2022 | - | $167.00 K(+32.5%) | $744.00 K(+4.8%) |
| Jun 2022 | - | $126.00 K(-29.2%) | $710.00 K(-19.2%) |
| Mar 2022 | - | $178.00 K(-34.8%) | $879.00 K(-5.6%) |
| Dec 2021 | $931.00 K | $273.00 K(+105.3%) | $931.00 K(-81.2%) |
| Sep 2021 | - | $133.00 K(-54.9%) | $4.94 M(-38.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | $295.00 K(+28.3%) | $8.08 M(-58.5%) |
| Mar 2021 | - | $230.00 K(-94.6%) | $19.47 M(-7.2%) |
| Dec 2020 | $20.99 M(+97.3%) | $4.29 M(+31.1%) | $20.99 M(+25.7%) |
| Sep 2020 | - | $3.27 M(-72.0%) | $16.71 M(+24.3%) |
| Jun 2020 | - | $11.69 M(+567.9%) | $13.44 M(+667.9%) |
| Mar 2020 | - | $1.75 M(-82.7%) | $1.75 M(-87.8%) |
| Dec 2018 | $10.64 M(+132.2%) | - | - |
| Jun 2018 | - | $10.14 M(+1940.8%) | $14.32 M(+209.4%) |
| Mar 2018 | - | $497.00 K(-82.1%) | $4.63 M(+1.0%) |
| Dec 2017 | $4.58 M(+579.8%) | $2.77 M(+205.3%) | $4.58 M(+103.0%) |
| Sep 2017 | - | $909.00 K(+102.4%) | $2.26 M(+67.4%) |
| Jun 2017 | - | $449.00 K(0.0%) | $1.35 M(+49.9%) |
| Mar 2017 | - | $449.00 K(-0.2%) | $899.00 K(+99.8%) |
| Dec 2016 | $674.00 K | $450.00 K | $450.00 K |
FAQ
- What is VYNE Therapeutics annual revenue?
- What is the all time high annual revenue for VYNE Therapeutics?
- What is VYNE Therapeutics annual revenue year-on-year change?
- What is VYNE Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly revenue year-on-year change?
- What is VYNE Therapeutics TTM revenue?
- What is the all time high TTM revenue for VYNE Therapeutics?
- What is VYNE Therapeutics TTM revenue year-on-year change?
What is VYNE Therapeutics annual revenue?
The current annual revenue of VYNE is $424.00 K
What is the all time high annual revenue for VYNE Therapeutics?
VYNE Therapeutics all-time high annual revenue is $20.99 M
What is VYNE Therapeutics annual revenue year-on-year change?
Over the past year, VYNE annual revenue has changed by -$53.00 K (-11.11%)
What is VYNE Therapeutics quarterly revenue?
The current quarterly revenue of VYNE is $121.00 K
What is the all time high quarterly revenue for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly revenue is $11.69 M
What is VYNE Therapeutics quarterly revenue year-on-year change?
Over the past year, VYNE quarterly revenue has changed by -$77.00 K (-38.89%)
What is VYNE Therapeutics TTM revenue?
The current TTM revenue of VYNE is $493.00 K
What is the all time high TTM revenue for VYNE Therapeutics?
VYNE Therapeutics all-time high TTM revenue is $20.99 M
What is VYNE Therapeutics TTM revenue year-on-year change?
Over the past year, VYNE TTM revenue has changed by +$7000.00 (+1.44%)